Cantor Fitzgerald analyst Josh Schimmer initiated coverage of Nuvalent (NUVL) with an Overweight rating and $135 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent’s Promising Oncology Prospects: A Buy Rating Driven by ALKOVE-1 Trial and Market Potential
- Nuvalent’s Promising Prospects: Buy Rating Backed by Pivotal Drug Readout and Strong Pipeline Potential
- Nuvalent Completes New Drug Application Submission
- Nuvalent presents data from ARROS-1 trial of zidesamtinib
- Nuvalent’s Promising Oncology Pipeline Drives Buy Rating with $111 Price Target